Skip to main content
. 2018 Apr 23;14(4):e1007012. doi: 10.1371/journal.ppat.1007012

Fig 2. Antagonizing KAT5 but not KAT7 or KAT8 reverses HIV latency and potentiates conventional LRAs.

Fig 2

A. D. & F. The Jurkat 2D10-based inducible CRISPRi-KAT5-sg1, CRISPRi-KAT7-sg1, and CRISPRi-KAT8 cells were treated with (+) or without (-) doxycycline (Dox) and analyzed by RT-qPCR for the KAT5/7/8 mRNA levels, which were normalized to those of ActB, and by Western blotting for the indicated proteins. B. E. & G. CRISPRi-KAT5-sg1, CRISPRi-KAT7-sg1, and CRISPRi-KAT8 cells were treated with or without Dox (1 μl/ml) and the various LRAs at the indicated concentrations. The treated cells were subjected to FACS analysis to determine the percentage of GFP(+) cells in each cell population. C. Wild-type 2D10 cells were treated with combinations of MG-149 and DMSO or the various LRAs at the indicated concentrations and subjected to FACS analysis as in B. Each column in all panels represents the average of three independent measurements, with the error bars indicating mean +/- SD.